WO2025237394 - FUSION PROTEIN FOR EPIGENETIC EDITING AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/237394
Publication Date
20.11.2025
International Application No.
PCT/CN2025/095303
International Filing Date
16.05.2025
Title **
[English]
FUSION PROTEIN FOR EPIGENETIC EDITING AND USE THEREOF
[French]
PROTÉINE DE FUSION POUR ÉDITION ÉPIGÉNÉTIQUE ET SON UTILISATION
[Chinese]
用于表观遗传编辑的融合蛋白及其应用
Applicants **
JUNFU BIOTECH (GUANGZHOU) CO., LTD.
Inventors
TAO, Milin
HU, Yang
CHEN, Yuxi
XIAO, Guiqin
LIANG, Feng
ZHU, Tingxia
Priority Data
202410613592.8
16.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2135 | |
| EPO | Filing, Examination, Granting | 14123 | |
| Japan | Filing, Examination, Granting | 2233 | |
| South Korea | Filing, Examination, Granting | 2246 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,477
Contact Us
Abstract[English]
Provided are a fusion protein and the use thereof in epigenetic editing. Specifically provided are a fusion protein and an epigenetic editor based on the fusion protein. A fusion protein, complex, fusion polypeptide, nucleic acid, vector, vector system, delivery system, cell, kit, and composition for epigenetic editing, and a method for silencing a target nucleic acid sequence in a cell are developed.[French]
L'invention concerne une protéine de fusion et son utilisation dans l'édition épigénétique. L'invention concerne spécifiquement une protéine de fusion et un éditeur épigénétique basé sur la protéine de fusion. Une protéine de fusion, un complexe, un polypeptide de fusion, un acide nucléique, un vecteur, un système de vecteur, un système de distribution, une cellule, un kit et une composition pour l'édition épigénétique, et un procédé de silençage d'une séquence d'acide nucléique cible dans une cellule sont développés.[Chinese]
提供了融合蛋白及其在表观遗传编辑中的应用。具体提供了融合蛋白以及基于该融合蛋白的表观遗传编辑器，开发了用于表观遗传编辑的融合蛋白、复合物、融合多肽、核酸、载体、载体系统、递送系统、细胞、试剂盒、组合物，以及沉默细胞中靶核酸序列的方法。